MQL in Life Sciences:
What Qualified Really Means

The standard MQL definition — a contact who has reached a scoring threshold based on content engagement and firmographic fit — was designed for simpler buying journeys. In life sciences, it rarely maps to how procurement actually works.

The buying committee reality

A clinical trial management software decision might involve the clinical operations director, a procurement officer, a data integrity lead, the chief medical officer, an IT security reviewer, and potentially a regulatory affairs consultant. Each has a different concern. Each needs different information. And a marketing team that’s counting a single MQL from a junior contact who downloaded a whitepaper is measuring something that doesn’t reflect the actual buying signal at all.

Why the individual-contact model of MQL fails

The MQL concept was built around an individual buyer making or heavily influencing a purchase decision. That model applies in some B2B contexts — SaaS tools with a single functional owner, for instance. It doesn’t apply in life sciences, where the concern isn’t whether one person is qualified but whether the organisation is ready to engage, who the relevant stakeholders are, and whether the right ones are in the room.

What a life sciences MQL definition should actually measure

Rather than scoring individual contacts, a more useful model scores account-level engagement: How many people from the target account have engaged with content? Which functions are represented? Has anyone from procurement or regulatory been in contact? Is there a confirmed project or budget cycle? These account-level signals are harder to track in a standard CRM but they reflect the actual buying process.

The content implication

If five different stakeholders need to be influenced before a deal moves, a content strategy built around one persona is structurally insufficient. Clinical directors care about outcomes data and regulatory positioning. Procurement cares about vendor risk and contract terms. IT cares about integration and security certification. A demand generation programme for life sciences needs content for each of these audiences — not just for the most accessible or most engaged one.

Aligning marketing and sales on what qualifies

In life sciences, the most productive alignment conversation between marketing and sales isn’t about MQL thresholds — it’s about account readiness signals. What does it look like when an account is genuinely in-cycle? Who do we need to have spoken to before a deal is worth pursuing? Getting sales to define those signals, and then building the marketing programme to generate them, produces a more useful handoff than a conventional MQL score.

Common questions

Should life sciences companies use MQL scoring at all?

Individual-contact MQL scoring has limited value in most life sciences contexts, but the underlying intent — distinguishing engaged accounts from cold ones — is still worth pursuing. Account-level engagement scoring (how many relevant contacts have engaged, from which functions) tends to be more predictive of deal readiness than individual lead scores. The metric should match the buying process, not the CRM default.

How do you market to a buying committee you can’t directly access?

Not every committee member will be reachable through marketing. The goal isn’t to reach all of them directly — it’s to give the contact you have access to the content that makes them credible and confident across functions. A case study that addresses procurement concerns alongside clinical outcomes gives a clinical operations lead something useful in an internal meeting, even if procurement never directly consumed the content.